Sofituzumab vedotin (
INN; development code DMUC5754A) is a monoclonal antibody designed for the treatment of
ovarian cancer.
This drug was developed by
Genentech
Genentech, Inc., is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within R ...
/
Roche.
Sofituzumab vedotin is an antibody-drug conjugate that targets MUC16, a protein that is overexpressed in several types of cancer including ovarian and pancreatic cancer. The conjugate consists of a human anti-nectin-4 antibody linked to the cytotoxic agent MMAE, which is released after internalization by the cancer cell. In addition to its direct cytotoxic effect, sofituzumab vedotin may also mediate antitumor activity through signal transduction inhibition, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity. Clinical trials have shown promising results in the treatment of ovarian and pancreatic cancer.
References
{{monoclonals for tumors
Monoclonal antibodies for tumors
Antibody-drug conjugates
Experimental cancer drugs